Detecting HER2 expression by IHC in lung cancer, the role of ADCs in targeting HER2 mutations, and the FDA breakthrough designation for trastuzumab deruxtecan are examined.
Data from the following clinical trials are discussed:
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non–small cell lung cancer: Interim results of DESTINY-Lung01. (Smit EF et al. 2020 ASCO annual meeting. Abstract 9504.)